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RESOURCE ARTICLE
Disease Ontology: improving and unifying disease annotations
across species
Susan M. Bello1,‡, Mary Shimoyama2, Elvira Mitraka3,*, Stanley J. F. Laulederkind2, Cynthia L. Smith1,
Janan T. Eppig1 and Lynn M. Schriml3
ABSTRACT
Model organisms are vital to uncovering the mechanisms of human
disease and developing new therapeutic tools. Researchers collecting
and integrating relevantmodelorganismand/orhumandataoftenapply
disparate terminologies (vocabularies and ontologies), making
comparisons and inferences difficult. A unified disease ontology is
required that connects data annotated using diverse disease
terminologies, and in which the terminology relationships are
continuously maintained. The Mouse Genome Database (MGD,
http://www.informatics.jax.org), Rat Genome Database (RGD, http://
rgd.mcw.edu) and Disease Ontology (DO, http://www.disease-
ontology.org) projects are collaborating to augment DO, aligning and
incorporatingdisease termsusedbyMGDandRGD,and improvingDO
as a tool for unifying disease annotations across species. Coordinated
assessment of MGD’s and RGD’s disease term annotations identified
new terms that enhance DO’s representation of human diseases.
Expansion of DO term content and cross-references to clinical
vocabularies (e.g. OMIM, ORDO, MeSH) has enriched the DO’s
domain coverage and utility for annotating many types of data
generated from experimental and clinical investigations. The
extension of anatomy-based DO classification structure of disease
improves accessibility of terms and facilitates application of DO for
computational research. A consistent representation of disease
associations across data types from cellular to whole organism,
generated from clinical and model organism studies, will promote the
integration, mining and comparative analysis of these data. The
coordinated enrichment of the DO and adoption of DO by MGD and
RGD demonstrates DO’s usability across human data, MGD, RGD
and the rest of the model organism database community.
KEY WORDS: Disease models, Mouse, Ontologies, Rat
INTRODUCTION
Model organism data associated with human disease is a rapidly
growing, valuable resource for clinicians and translational and basic
science researchers, as well as bioinformaticians, seeking to
discover new genetic disease associations and analyze individual
or population disease susceptibilities. However, without the use of a
common structured disease vocabulary, access to these data requires
collecting data from various model organism databases and the
scientific literature, collating the amassed information, and aligning
the different terminologies used in each resource.
For example, to identify the mouse and rat models of Alzheimer
disease, a researcher would need to collate information from dozens
of Mouse Genome Database (MGD; Eppig et al., 2017) and Rat
Genome Database (RGD; Hayman et al., 2016) webpages,
application programming interfaces (APIs) or downloadable files.
Then he/she would need to align the Online Mendelian Inheritance
in Man (OMIM; Amberger and Hamosh, 2017) terms used in the
MGD annotations with the corresponding terms from Rat Disease
Ontology (RDO; Hayman et al., 2016) used in RGD annotations to
determine when the mouse and rat were modeling the same subtype
of Alzheimer disease. Further, he/she would need to determine
whether the disease modeled corresponds to the one discussed in a
reference tagged with a Medical Subject Headings (MeSH, https://
www.ncbi.nlm.nih.gov/mesh) term or to the Orphanet (Rath et al.,
2012) Rare Disease Ontology (ORDO) term associated with a
particular gene. Such extensive collecting and aligning of different
terminologies can significantly hamper studies and analyses and/or
lead to conflicting conclusions if definitions among vocabularies
are inconsistent. In addition, computational tools developed to take
advantage of model organism data in a clinical setting must
download and integrate data from multiple resources to have the
greatest chance of analytical success (Hoehndorf et al., 2015;
Orechia et al., 2015; Patterson et al., 2016; Vitali et al., 2016).
Having a single disease ontology with cross-references to multiple
disease vocabularies incorporating both etiology- and anatomy-
based views will greatly simplify and enhance the efficiency of
disease-related searches within and across species.
Multiple clinical disease vocabularies have been developed for
specific cases of use [e.g. International Classification of Diseases
(ICD): morbidity and mortality reporting, as described in Schriml
and Mitraka, 2015]. However, these are not necessarily compatible
with the data-collection needs for disease models or human clinical
data. In the past, MGD and RGD struggled to find a comprehensive
and appropriately structured, defined vocabulary for human disease
annotations (Bello et al., 2012). Prior to the current work described
here, MGD used OMIM and RGD used RDO (developed by RGD)
for human disease annotations. The RDO includes terms from the
Comparative Toxicogenomics Database’s ‘MErged DIsease
voCabulary’ [MEDIC; a combination of the MeSH ‘Diseases’
branch (branch ‘C’) and OMIM terms (Davis et al., 2012)] and an
RGD-supplemented custom vocabulary of over 1600 terms.
However, neither RDO nor OMIM were fully sufficient for the
needs of disease annotation and disease data integration in
MGD and RGD (Table 1). For MGD, many mouse models fall
outside the scope of OMIM. Additionally, RGD’s custom terms areReceived 31 October 2017; Accepted 8 February 2018
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not fully mapped to other disease vocabularies. Also, the structure
of MeSH, inherent in the RDO vocabulary, does not support
computational reasoning across the vocabulary (Fernandez-Llimos
et al., 2017).
To be suitable for disease model annotation, a vocabulary needs
to meet several criteria (Table 1). These criteria include: a
sufficiently broad scope, cross-references for integration across
disease resources, stability and maintenance of the vocabulary, a
structure that supports reasoning over the vocabulary, permanent
stable identifiers, and support for multiple types of users (see
below). Several different vocabularies have been evaluated byMGD
and RGD, including OMIM, MeSH, MEDIC, RDO, ORDO and
Disease Ontology (DO; Schriml and Mitraka, 2015). Two major
medical terminologies were not included in the evaluation, the ICD
and the Systematized Nomenclature of Medicine (SNOMED)
vocabularies. The ICD vocabularies, developed primarily for
medical billing, contain many non-disease terms related to
injuries and medical procedures that would require extensive
filtering prior to use. The SNOMED vocabulary was excluded
due to licensing issues for non-US users. Each of the evaluated
vocabularies was developed for a specific purpose that was related
to the annotation needs of MGD and RGD. OMIM strives to be the
full catalog of human Mendelian phenotypic variation and includes
extensive written histories of Mendelian diseases and their range of
expression. ORDO is a structured vocabulary for rare diseases,
capturing defined relationships between diseases, populated from
literature and validated by international experts. In addition to
disease records, both OMIM and Orphanet create mappings
between their disease terms and the genes and genomic features
linked to these diseases. MeSH is designed to index biomedical
information in the National Library of Medicine’s databases,
including MEDLINE and PubMed. The DO’s primary purpose is to
provide the biomedical community with a consistent, reusable and
sustainable resource for descriptions of all human diseases with
extensive cross-mapping to other disease vocabularies. DO provides
a unified etiology-based human disease classification, maintaining
up-to-date disease nomenclature with extensive cross-references
to National Cancer Institute (NCI) Thesaurus, OMIM, MeSH,
ICD9CM, ICD10, ICD10CM, Orphanet, National Organization for
Rare Disorders (NORD), SNOMED Clinical Terms (CT), Unified
Medical Language System (UMLS), Experimental Factor
Ontology (EFO) (Kibbe et al., 2015) and custom subsets (e.g.
DO_FlyBase_slim, DO_rare_slim, DO_cancer_slim, DO_AGR_
slim). DO utilizes OMIM as the authoritative resource for
Mendelian genetic diseases.
Criteria for use in disease model annotation
Scope
Both MGD and RGD capture a wide variety of data on human
disease models in rodents. These diseases range from classical
single gene Mendelian diseases to complex multi-genic diseases to
disease susceptibility genes to diseases caused by environmental
conditions, and include both rare and common diseases. Therefore,
any disease ontology adopted for use by MGD or RGD needs to
include in its scope the full range of disease types represented in
rodent disease models.
Of the vocabularies reviewed – DO, MeSH, MEDIC and RDO –
all have a broad scope that encompass the full range of disease types
captured by MGD and RGD. OMIM and ORDO each have a
restricted scope that does not encompass all of the types of diseases
captured by MGD and RGD. OMIM excels at covering Mendelian
diseases, providing a rich source of information for users and
physicians, but does not systematically capture non-Mendelian or
environmentally induced diseases. ORDO captures mainly rare
diseases and has entries for only select common or environmentally
induced diseases. For example, DO, MeSH, MEDIC and RDO all
have a term for ‘Parkinson disease’, but OMIM and ORDO only
have terms for specific subtypes of Parkinson disease, such as
Parkinson disease, late-onset (OMIM:168600) or rare parkinsonian
disorder (ORPHA:68402).
Cross-references
A major goal for both MGD and RGD is to provide easy translation
between model organism data and human data. To make this
translation, any disease vocabulary used needs to support the
integration of disease data annotated using multiple different
terminologies. The presence of vocabulary cross-references
enables this translation and also enhances the ability of users to
search using their preferred vocabulary term and find the related
data. The cross-references in both DO and ORDO include all the
disease resources used by MGD and RGD for annotations.
However, neither includes all of the cross-reference identifiers
used in both MGD and RGD annotations. For example, both DO
and ORDO include cross-references to OMIM but neither includes
all of the OMIM IDs used by MGD in their cross-references.
Similarly, both include MeSH identifiers as cross-references but
neither has all of the MeSH IDs used by RGD.
Defined relations between terms
To support computational users and bioinformatics tool development,
disease model annotations need to be made to a vocabulary with
Table 1. Criteria for disease annotation vocabulary
Criteria Reason DO ORDO OMIM MeSH MEDIC RDO
Broad coverage Need to cover a wide range of
diseases
Yes Restricted Restricted Yes Yes Yes
Cross-references Need to allow for integration of data
across disease resources
Needs
expansion
Needs
expansion
No No Needs
expansion
Needs
expansion
Defined relations
between terms
Need to support bioinformatics
researchers and tools
Yes, needs
expansion
Yes, needs
expansion
No No No Yes, needs
expansion
Stable identifiers Meanings attached to term IDs need
to be stable
Yes Yes No Primary identifier
varies depending on
the MeSH branch
No (MeSH and
OMIM IDs)
Yes
Include both specific
and generic disease
classes
Need to accommodate models for
broad classes of disease and
models of unknown etiology
Yes Yes Partially Yes Yes Yes
On-goingmaintenance Need to adjust to changes in
knowledge about disease
Yes Yes Yes Yes Yes Yes
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robust defined relations between terms. Defined relationships
between two ontology terms are captured using the Open
Biological and Biomedical Ontology (OBO) Foundry’s Relation
Ontology (RO, Smith et al., 2005); this allows data annotated to a
highly specific (child) term to be inferred to be associated with all of
the less specific (parent) terms that are related to it. For example, all
mouse and rat models annotated to ‘autosomal recessive early-onset
Parkinson disease 6’ (DOID:0060369) can also be inferred to be
models of the parent term ‘early-onset Parkinson disease’
(DOID:0060894) and its parent term ‘Parkinson’s disease’
(DOID:14330).
DO, RDO and ORDO use defined RO relationships in their
ontologies. The DO primarily uses the ‘is a’ relation to indicate that a
disease is a subtype of a broader disease class. ORDO uses a variety
of relations, including ‘is a’ (for subtypes) and ‘part of’ (for diseases
that span multiple broader classes). The RDO has defined all relations
for both MEDIC terms and supplemental terms as ‘is a’ relations.
However, because the structure is inherited from MeSH, which does
not have an ontological structure, this can result in some questionable
assertions for RDO. For example, Genital Neoplasms, Male
(RDO:0005657) has the parent term Urogenital Neoplasms
(RDO:0005656), but Urogenital Neoplasms has ‘is a’ relations to
both Male Urogenital Diseases (RDO:0005655) and Female
Urogenital Diseases (RDO:00005654) (https://rgd.mcw.edu/
rgdweb/ontology/view.html?acc_id=DOID:9007150). Reasoning
over RDO would result in the transitive assertion that Genital
Neoplasms, Male is a subtype of Female Urogenital Diseases.
Although there are connections between terms, these connections do
not use RO-based defined terms that support computational
reasoning. In MeSH, the connection between terms is further
complicated by the fact that connections are dependent upon the
branch of the vocabulary you are viewing. OMIM classifies the
phenotype descriptions as autosomal, X linked, Y linked or
mitochondrial in a non-hierarchical vocabulary with related
phenotypes grouped into phenotypic series [e.g. the Parkinson
disease phenotypic series (OMIM:PS168600) includes 30 OMIM
records].
Stable identifiers
To minimize the need to review and revise existing annotations
and to enable tracking of nomenclature changes over time, the
disease vocabulary should have a stable relationship between an
identifier and the meaning of a term attached to that identifier.
Although this is a staple of ontology development (Smith et al.,
2007), it is not a requirement when building a vocabulary or
encyclopedia of diseases, nor should it be assumed that all such
resources are built in the same way. For example, OMIM retains
identifiers but may update the content related to a specific
identifier such that the new phenotype object attached to the
identifier is significantly different from the old phenotype object.
For example, OMIM:168600 was revised from ‘Parkinson
Disease’ to ‘Parkinson Disease, Late-Onset’. It is important to
assess all ID to term changes for any resource utilized for
annotation to capture data updates.
Inclusion of both specific and generic disease classes
Disease vocabularies, such as DO, provide the structure to enable
disease models to be associated with a generic (parent) disease class
or to specific subtypes. This is critical for annotation because
disease models are not always made for a specific subtype of a
disease. For example, there are many mouse models of Parkinson
disease that cannot be associated with a specific subtype of
Parkinson disease as delineated in OMIM (27 of 78 models in
MGD). These mouse models may be strains, complex genetic
models or environmentally induced models. For each case, there is a
need to associate the model with the disease term at the appropriate
level of specificity, whether to the general term Parkinson Disease
or to one of the specific Parkinson disease subtypes (e.g. Parkinson
Disease 6).
DO, ORDO, MeSH and MEDIC all include hierarchies with
generic diseases and broad disease classes. OMIM does not include
generic disease types or broad disease classes. However, OMIM has
recently added phenotypic series for some diseases (e.g. Parkinson
disease) that collect members of the closely related disease families.
These series have been extremely helpful throughout this project.
On-going content and nomenclature maintenance
As disease knowledge continues to expand and evolve, disease
vocabularies need to remain up-to-date with current knowledge.
Additionally, cross-references to disease vocabularies need to be
updated as other resource vocabularies change. All vocabularies
reviewed work to incorporate the latest changes in disease
understanding.
Of the disease vocabularies reviewed, only DO fulfills all of the
criteria described above. Importantly, DO has the broad scope needed
to cover the different types of disease models captured by MGD and
RGD, the defined structure needed to support computational users,
and includes in its goals the maintenance of cross-references to many
other disease resources (Schriml and Mitraka, 2015). Having
concluded that DO was the best option for disease curation for both
MGD and RGD, a collaboration was begun betweenMGD, RGD and
DO to expand and enhance select areas of DO to improve coverage of
existing MGD and RGD disease annotations in each database and
improve discovery of diseases based on the needs of users of both
databases. This work initially focused on increasing the coverage of
cross-references (OMIM and MeSH) in use for MGD and RGD
disease model annotations, expanding the types of relationships
between disease terms to include ‘contributes to condition’ for
OMIM susceptibility to a disease term, and increasing the number of
anatomy-based ‘located in’ definitions for DO terms to improve
accessibility of disease data using DO. Below are the results of the
ongoing collaboration between MGD, RGD and DO to enhance and
expand the DO.
RESULTS
Disease collaborative coordination efforts
To coordinate disease-term reviews and updates, the MGD and
RGD teams identified and shared with the DO team the subset of
their disease terms where the term identifier was not already cross-
referenced to a Disease Ontology ID (DOID) at the onset of this
project. The shared files (disease term, RDO ID, OMIM ID,
suggested parent term mappings) enabled collaborative review and
addition of terms and cross-references into DO, and continue to
foster ongoing discussions between the teams and provide MGD
and RGD with updated DO term mappings. The team reviewed and
classified each term and determined which terms were within the
scope of DO, with only a small set of terms identified to be
symptoms, injuries or phenotypes. GitHub tickets for ongoing work
were entered in the public DO issue tracker (https://github.com/
DiseaseOntology/HumanDiseaseOntology/issues). The use of a
public issue tracker allows the MGD, RGD and DO teams, and
additional interested parties, to access and track progress (Table 2).
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Addition of cross-references
Disease identifiers in use by either MGD or RGD for disease
annotation were compared to existing cross-references in DO to
create a targeted set of potential new identifiers (Table 3) for
addition to DO. The potential new cross-reference terms were
reviewed to determine whether the disease term attached to the
identifier (1) corresponded to an existing DO term, (2) represented a
term within the scope of DO that should be added or (3) fell outside
the scope of DO. Identifiers for disease terms that corresponded to
existing DO terms were added as cross-references for the
appropriate term. Terms that fell within the scope of DO but
represented new diseases were collected for review and addition to
DO. As part of the review, additional cross-references from other
disease vocabularies were identified and added to DO.
Of the 1440 OMIM terms with mouse model annotations in MGD
for the first round of review in December 2015, 1178 were already in
DO, whereas 262 were identified for potential inclusion. This review
was repeated in August 2016, at which point 379 OMIM terms were
identified for review and potential inclusion in DO. This second
review included terms from the 2015 review that had not yet been
added to DO as well as new terms used in MGD annotations. In
addition, the 2016 review identified OMIM terms with a human gene
association that were not yet in DO. This second set contains terms
also found on the list of terms with mouse models.
Of the 9435 RDO terms in use by RGD, 4605 were already in
DO, whereas 4830 were reviewed for potential inclusion. RGD
selected 565 terms for detailed review. To date, 164 of these have
been reviewed and 48 were determined to be outside the scope of
DO, whereas 116 were mapped to extant DO terms or used to create
new DO terms. As part of the review process, additional terms
closely related to the targeted term were identified; for example, if
the target term is a member of an OMIM phenotypic series, then all
members of the series would be reviewed and added to DO along
with the targeted ID. Thus, the number of new cross-references
often exceeds the number of targeted identifiers.
DO includes in its scope all human disease, but the reviews
identified terms in use byMGD and RGD that fell outside this scope.
These terms were reviewed and handled in different ways depending
on the term. For MGD, there were two different sets of terms that fell
outside the scope of DO. One set of these, the OMIM disease
susceptibility terms, contributed to the expansion of relationships in
DO (see below). The second set consisted of OMIM gene plus
phenotype records that describe both a gene and one or more
phenotypes or diseases associated with that gene. OMIM is actively
working to eliminate this type of record – currently there are only 77
of these left out of 8000 OMIM phenotype entries (Ada Hamosh,
Johns Hopkins University School of Medicine, personal
communication) – and a review of MGD annotations is required to
identify the diseases being modeled. For RGD, a significant number
(>140) of terms were determined to be outside of DO’s scope. These
primarily related to injury (e.g. Acute Kidney Injury, RDO:0001702),
infection (e.g. Cardiovascular Infections, RDO:0005485) or signs/
symptoms (e.g. Diabetic Foot, RDO:0007073). RGD is continuing to
use RDO to capture these annotations.
Identification of novel disease classes
Both MGD and RGD need to incorporate disease mentions in
publications that do not match an existing term in OMIM (MGD) or
RDO (RGD). For MGD, these annotations are captured in the
database in note fields and represent over 360 distinct diseases. These
diseases are typically generic disease classes, such as heterotaxy,
polycystic kidney disease or inflammatory bowel disease. RGD
captures similar types of annotations by adding terms to RDO. RGD
has added over 1700 terms to RDO to cover a range of diseases, from
specific types of retinitis pigmentosa to acute pancreatitis (Hayman
et al., 2016). Terms from both of these sets were compared with those
in DO to determine whether they could be mapped to existing DO
terms, represented diseases within the scope of DO that should be
added, or fell outside the scope of DO (Table 3).
As part of the conversion from OMIM to DO at MGD, the
alignments to DO created during this project were used to guide the
annotation of the 600 mouse alleles with disease annotations in note
fields. For MGD, this resulted in the addition of over 1070 new
disease model annotations to DO disease terms for 330 different
diseases. This review also identified 31 potential new DO disease
terms that are in the process of being reviewed for addition to DO. In
most cases, these new terms are more specific subtypes of existing
DO disease classes.
Refinement of OMIM cross-references
During the review and initial implementation of use of the DO at
MGD and RGD, a need was identified to refine the OMIM cross-
references in DO so that the mappings were made at a higher degree
of granularity. OMIM IDs for multiple subtypes of a disease were
frequently all associated with a generic term for the disease. This
grouping of OMIM IDs complicates the differentiation of
etiologically similar models from the full set of models. This
Table 2. DO GitHub tickets
Task Ticket link
Addition of OMIM cross-
references for terms used by
MGD
https://github.com/DiseaseOntology/
HumanDiseaseOntology/issues/193
Addition of OMIM susceptibility
terms using the ‘contributes to
condition’ relation
https://github.com/DiseaseOntology/
HumanDiseaseOntology/issues/386
Expansion of the anatomy-based
view using the ‘located in’
relationship
https://github.com/DiseaseOntology/
HumanDiseaseOntology/issues/328
Review of OMIM terms cross-
referenced to multiple DO
terms
https://github.com/DiseaseOntology/
HumanDiseaseOntology/issues/196
Addition of new disease terms
from MGD annotations
https://github.com/DiseaseOntology/
HumanDiseaseOntology/issues/358
Table 3. Use of MGD and RGD annotations to identify areas for expansion in the DO
Database Vocabulary
No. terms in use by
MGD or RGD
No. used terms
missing from DO
No. new
cross-references
New
terms
MGD-2015 OMIM 1440 262 (mouse) 1868 – OMIM
622 – ORDO
130 – ICD10
77 – UMLS
59 – MeSH
1267
MGD-2016 OMIM 1486 379 (mouse)
1723 (human)
RGD MEDIC 7682 3800
RDO/custom 1753 1030
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grouping also complicates the translation of annotations made to
OMIM terms by other resources. For example, the Human
Phenotype Ontology (HPO) annotations (Köhler et al., 2017) are
made directly to human disease terms from OMIM and ORDO. The
grouping of multiple distinct OMIM or ORDO diseases into a single
DO term results in HPO annotations for distinct subsets being
merged into a common description, which may or may not
accurately reflect the specific individual disease phenotypes.
Thus, the decision was made to create individual entries for
members of OMIM series whenever appropriate.
The initial review focused on 229 OMIM phenotypic series
where annotations existed either in MGD or HPO (see Ticket link
in Table 2). To date, 99 of these series have been reviewed,
resulting in the addition of 815 new DO terms associated with
over 1000 cross-references. For example, all of the OMIM cross-
references for the OMIM phenotypic series ‘Osteogenesis
imperfecta’ (OMIM:PS166200) had been associated with the
DO term ‘osteogenesis imperfecta’ (DOID:12347). After review,
individual DO terms were created for each member of the OMIM
series and the appropriate cross-references (e.g. OMIM, ORDO
and ICD10 IDs) added to the new DO term (Fig. 1). The OMIM
phenotypic series ID was also entered as a cross-reference to
the parent DO term. This process increased both the
granular resolution of DO and refined the cross-reference
relationships in DO.
Expansion of DO relationship types
Addition of OMIM susceptibility terms
A number of MGD annotations had been made to OMIM
susceptibility terms (e.g. ‘susceptibility to Alzheimer disease 9’,
OMIM:608907; ‘susceptibility to malaria’, OMIM:611162). These
terms represent susceptibility to the disease and not the disease
itself, and are therefore outside the scope of DO. In these cases,
adding the OMIM ID as a cross-reference to the DO term would be
incorrect. However, creating a relationship between the OMIM ID
and the DOID was desirable, as this allows the translation of
associations between human genes and disease susceptibility in
OMIM into associations between a human gene and DO term.
Retaining access to this valuable set of gene annotations was
deemed a high priority. To accomplish this, a new relationship was
added to the DO, ‘contributes to condition’ (RO:0003304), and
used to link OMIM susceptibility terms to DO terms. The
‘contributes to condition’ relationship is defined in RO as ‘A
relationship between an entity (e.g. a genotype, genetic variation,
chemical, or environmental exposure) and a condition (a phenotype
or disease), where the entity has some contributing role that
influences the condition’.
A list of 181 OMIM susceptibility terms was created by searching
the OMIM database. A review of this list identified 135 OMIM
susceptibility terms that referred to a disease represented by a DO
term. These terms were added to the DO file and connected to the
related disease using the ‘contributes to condition’ relationship. For
example, the OMIM term ‘susceptibility to malaria’ was related to
the DO term for malaria (DOID:12365) via the ‘contributes to
condition’ relationship (Fig. 2), allowing the OMIM gene
information to be connected to the DO disease term.
The remaining 45 OMIM terms that do not reference an extant
DO term fall into several classes. The largest class are terms that
refer to susceptibility to infection by a type of bacteria or virus (e.g.
susceptibility to herpes simplex encephalitis 1, OMIM:610551;
susceptibility to mycobacterium tuberculosis, OMIM:607948).
Others refer to susceptibility to develop disease-related
human 
gene(s)
Osteogenesis Imperfecta in DO pre-division Osteogenesis Imperfecta in DO post-division
14 human genes 
OI1 …
1 OMIM 
cross-
reference …
human 
gene(s)
1 OMIM 
cross-
reference
human 
gene(s)…
OI2 OI7
1 OMIM 
cross-
reference
osteogenesis
imperfecta
20 OMIM 
cross-references
osteogenesis
imperfecta
Fig. 1. Division of osteogenesis imperfecta (OI) terms in DO. Increasing the granularity of OI terms in DO (shown on the right) allows for refined relationships of
OMIM gene-to-disease associations (dotted arrows) to equivalent DO terms via OMIM cross-references to DO terms (solid arrows).
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complications (e.g. susceptibility to microvascular complications of
diabetes 1, OMIM:603933) or to develop a phenotype (e.g.
susceptibility to intracerebral hemorrhage, OMIM:614519). These
terms will require further review to determine whether an
appropriate mapping to a DO term can be created.
Enrichment of anatomy-based relations
The DO uses the primary etiology of a disease to define the single
asserted ‘is a’ relationship for each disease in DO (Schriml et al.,
2012). However, not all users approach disease from the perspective
of the primary cause(s). To meet the needs of users that approach
disease from an anatomy-based perspective, an anatomical system-
based review of DO was undertaken to identify terms where the
addition of a ‘located in’ (RO:0001025) relationship to an
anatomical term would enhance the usability of the DO for these
users. For example, although, from an etiological perspective,
cancers of the brain should be placed under cancer, a user with an
anatomy-based perspective would expect to see this under brain
disease. The addition of anatomy-based relations to a term allows
for multiple parents to be inferred and displayed, thus meeting the
needs of both sets of users. The cross-species anatomy ontology,
UBERON (Mungall et al., 2012), is used for anatomy terms in these
relationships as this ontology has been adopted by many other
groups to facilitate cross-species comparisons. In the brain cancer
example, the addition of a ‘located in’ relation to the UBERON
anatomy term ‘brain’ (UBERON:0000955) and use of the
UBERON structure allows us to infer the additional parent of
‘brain disease’. Thus, in MGD and RGD, ‘brain cancer’ is displayed
under both the nervous system and cancer branches of the DO
(Fig. 3). The review of diseases for addition of anatomy-based
‘located in’ information was made on a system basis. Initial reviews
of the cardiovascular system disease and neurological disease
branches have been completed. The DO now contains over 1000
‘located in’ relationships. A breakdown of the spread of terms with
these relationships in the branches of the DO is shown in Table 4.
This total includes both the relationships added as part of the
cardiovascular and neurological system reviews and ‘located in’
relationships that were added as part of other term reviews and new
term additions.
Identification of diseases in need of review
In some cases, placement of a disease term in the DO hierarchy is
not straightforward. These are typically cases where different
competing organization schemes of a disease series exist. These
require more in-depth literature review and in some cases may
require consultation with external medical experts. Classification of
Parkinson disease illustrates this point, with over 20 subtypes
defined in OMIM. Parkinson disease was classified into juvenile-,
early- and late-onset based on the GeneReviews 2014 article,
‘Parkinson disease overview’ (Farlow et al., 2004). More granular
DO terms corresponding to the OMIM subtypes were then assigned
to the broader classes, unifying the classification approaches. In
some cases the different vocabularies use classification schemes
using different criteria. For example, Cockayne syndrome is
classified by OMIM based on complementation groups (CSA,
CSB) but in Orphanet based on phenotypic severity (CS1, CS2,
CS3). OMIM initially had a record for CS3 (OMIM:216411) but,
after discussions with OMIM leaders Ada Hamosh and Joanna
Amberger, the OMIM record for CS3 was obsoleted as this had a
single reference and does not correspond to the Orphanet record for
CS3. Because of the competing classification approaches, the
OMIM and Orphanet identifiers were not split out into subclasses.
Experts will be consulted to clarify this disease.
Refinement of existing OMIM cross-references
In a small set (53) of cases, the same OMIM ID was attached to
more than 1 DO term. Those with MGD annotations (24 of 53)
were reviewed to determine whether the duplicate placement
was appropriate. In 17 of the 24 cases, the OMIM ID was
removed from one of the DO terms. Most of these resulted from
the OMIM record containing both a main disease entity (what
the ID refers to) and an included disease entity (not what the ID
refers to). For example, in OMIM, mast cell disease
(OMIM:154800) includes the ‘included entity’ urticaria
pigmentosa. As these are distinct diseases, using a single
OMIM ID as a cross-reference for both would lead to incorrect
inferences across the ontology. The remaining 8 cases required
more extensive review and resulted in removal of the OMIM ID
from both of the original DO terms.
Mix of Disease and Susceptibility terms as 
Cross-References
Separation of Disease Cross-References and 
Susceptibility Relationships
OMIM:609148
mild susceptibility 
to malaria
EFO:0001068
malaria
MESH:D008288
malaria
OMIM:609148
mild susceptibility 
to malaria
EFO:0001068
malaria
MESH:D008288
malaria
malaria malaria
Fig. 2. Addition of ‘contributes to condition’ relations to DO. Prior to this project, OMIM cross-references in DO contained a mix of primarily disease records
plus a few ‘susceptibility to disease’ records (shown on the left). The addition of the new relation allows disease cross-references to be computationally
distinguished from relationships between a disease and a susceptibility to that disease (shown on the right). Solid lines represent cross-references; dotted lines
represent the ‘contributes to condition’ relationship.
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Overall expansion and enrichment of DO
As a result of this project, many new DO terms and cross-references
have been added to DO. Over 1200 new DO terms were added.
These include both terms for diseases that were missing from DO
and terms that were created to represent subtypes of specific
diseases. All new DO terms have a textual definition, and relevant
cross-references from OMIM, ORDO, ICD10 and MeSH were
added. The cross-references include over 1800 OMIM IDs, 620
ORDO IDs, 130 ICD10 IDs and 60 MeSH IDs. This covers
approximately 90% of the terms currently used by MGD. To date,
the collaborative review process also resulted in substantial updates
to existing DO cross-references and the development of procedures
for ongoing work on the DO. For example, MGD now supplies DO
with weekly lists of new OMIM terms and changes to OMIM term
meanings based on existing MGD quality control (QC) processes.
Release of DO files
To meet the needs of different user groups, the DO produces
different versions of the ontology. These include both OWL and
OBO formatted versions of the file. Both simple (including only the
asserted ‘is a’ etiology-based relationships) and merged (including
both asserted and inferred relationships) are produced in each of the
formats. New versions are produced following each approximately
monthly release. These files can all be found on the DO GitHub site
(https://github.com/DiseaseOntology/HumanDiseaseOntology).
MGD and RGD both import the merged versions of the file that use
the ‘located in’ and ‘contributes to’ relationships. For more details
on the production and release of DO files, please see the DOGitHub
site.
DISCUSSION
The requirement for a robust disease ontology designed to support
model organism disease annotations is shared by more groups than
just MGD and RGD. The additions and enhancements made to DO
as well as refinements made to the systems for requesting changes
and additions make DO an excellent choice for model-based human
disease annotations. Both MGD and RGD have converted or
mapped, respectively, their systems to use the DO even while the
work continues. In addition, the newly formed Alliance for Genome
Resources (AGR, http://www.alliancegenome.org) has chosen to
use DO for all disease annotations. Besides MGD and RGD, the
AGR includes model organism databases for zebrafish (ZFIN),
Drosophila (FlyBase), Caenorhabditis elegans (WormBase) and
Saccharomyces cerevisiae (SGD). Implementation of use of the DO
at MGD has already enhanced our ability to integrate data:
annotations made by the HPO team to Orphanet diseases are now
brain
cancer
central nervous 
system cancer
nervous system 
cancer
organ system 
cancer
cancer
disease of cellular 
proliferation
disease
central nervous 
system cancer
nervous system 
cancer
organ system 
cancer
cancer
disease of cellular 
proliferation
disease
brain
disease
central nervous 
system disease
organ system 
cancer
cancer
disease of cellular 
proliferation
located_inbrain
located_in‘central 
nervous system’
brain
cancer
Asserted Hierarchy Asserted and Inferred Hierarchy
Fig. 3. Addition of ‘located in’ axioms and the derivation of additional ‘is a’ disease relationships. Solid arrows indicate asserted relationships in DO;
dashed lines indicate relationships inferred from anatomy-based axioms.
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integrated in the Human-Mouse: Disease Connection tool (http://
www.informatics.jax.org/humanDisease.shtml, Blake et al., 2017)
at MGD. Prior to the DO implementation, MGD was unable to
integrate these annotations with the existing OMIM annotations. A
detailed description of the conversion/mapping to DO byMGD and
RGD will be detailed in subsequent publications.
Expansion of the relationships in DO to include inferred ‘is a’
relationships based on ‘located in’ information has enhanced the
accessibility of diseases based on different viewpoints. For example,
benign renovascular hypertension (DOID:13145) had an asserted
relationship to benign secondary hypertension (DOID:13143) but
lacked a relationship to renal hypertension (DOID:1073). Thus, a
user browsing kidney diseases would have missed data related to
benign renovascular hypertension. The addition of a new
relationship based on the information that this disease is located
in the kidney allows for improved recall of the disease data for both
manual and computational users.
The introduction of over 1200 new terms, 1900 cross-references
and 1100 new relationships between terms has greatly enhanced the
utility of DO for MGD, RGD and other model organism databases.
A breakdown of where these terms fall within the DO hierarchy is
shown in Table 4. The collaboration between MGD, RGD and DO
is ongoing. Adoption of DO by this wide range of model organism
databases will help to identify additional areas for expansion and
enrichment. In addition, these changes will benefit the many tools
and resources already using DO [e.g. Jax-CKB (Patterson et al.,
2016); Triple-Negative Breast Cancer Database (Vitali et al., 2016),
OncDRS (Orechia et al., 2015), QueryOR (Bertoldi et al., 2017),
Disease Compass (Kozaki et al., 2017), DisSim (Cheng et al., 2016)
and UniCarbKB (Campbell and Packer, 2016)] by increasing the
amount of data these tools can import from other resources.
This collaborative effort has helped speed the integration of the
diverse ecosystem of disease resources. The careful review of terms
and refinement of cross-references will increase both the coverage
of terms that can be retrieved as well as the accuracy of retrieved
data. Having efficient, reliable and thorough integration of disease
resources is a key element in bringing precision-medicine forward.
Tools such as those for candidate gene analysis, tumor
classification, drug repurposing and cancer variant analysis [e.g.
CIViC (https://civic.genome.wustl.edu/home; Griffith et al., 2017)]
require access to as much data as possible in order to provide
researchers and clinicians with an accurate picture of our current
understanding of disease. This project and the continued
development of DO are essential in these efforts.
MATERIALS AND METHODS
Data collection
Scripts were run against the MGD and RGD databases on multiple
occasions (12/2015 through 7/2017) to collect disease vocabulary terms in
use in each database. Disease terms annotated to mouse or rat models with
IDs not present in the DO file were output in files and shared using Google
docs. Additional scripts were run against MGD to identify DO terms with
multiple OMIM cross-references that also had mouse or HPO annotations.
Annotation counts included in the outputs were used to prioritize more
frequently used terms for review. OMIM terms cross-referenced to multiple
DO terms and obsolete OMIM terms included in the DO file were identified
using MGD QC reports during the implementation of the DO at MGD.
Outputs from the scripts and QC reports can be accessed through issue
tracker tickets on the DO GitHub site (Table 2). Data for Table 4 were
extracted from the DONovember 2017 release.MouseMine (Motenko et al.,
2015) was used to derive the counts of terms for each DO branch.
Term review and addition
The output of the scripts was manually reviewed to identify (1) OMIM IDs
that were missing as cross-references in the DO (2) OMIM and RDO
IDs that represented terms missing from the DO and (3) OMIM and RDO
IDs representing terms that were out of scope for the DO. Multiple human
disease resources (Table 5) as well as primary research articles were used
during the review process. To facilitate new term addition, a standard
definition template was developed and used whenever possible. This
template has the form: ‘A [disease parent term] characterized by
[distinguishing phenotype(s)] that has_material_basis_in [mutation type
or zygosity] in [gene or genetic region] on [chromosome]’, where the square
brackets were filled in with the relevant information. Term additions to the
doid-edit.owl file were made either manually using Protégé 5.1 or by using
the ROBOT tool (https://github.com/ontodev/robot). Terms were added
using DOIDs rather than incorporating (MIREOTing) IDs from other
vocabularies for several reasons, including: (1) DO is a domain ontology
and thus uses DOIDs for terms, (2) ease of use of the ontology in curation,
(3) avoiding incorporation of unstable identifiers and (4) integration of terms
with the same meaning from multiple vocabularies into a single DO entry.
Consistency of the ontology is checked using the ELK 0.4.3 reasoner.
Members of the MGD, RGD and DO teams continue with their regular
conference calls and periodic in-person meetings to discuss ongoing
additions and modifications to DO and expansion of cross-references and
term relationship representations. These calls facilitate a dynamic response
to both changes in disease knowledge and the evolving needs of curation at
MGD and RGD.
Table 4. Breakdown of addition of ‘located in’ relationships and new
disease terms to DO hierarchy1
DO branch
No. ‘located
in’ terms
No. new terms
added
Disease by infectious agent 19 0
Bacterial infectious disease 10 0
Parasitic infectious disease 3 0
Disease of anatomical entity 762 821
Cardiovascular system disease 53 64
Endocrine system disease 45 34
Gastrointestinal system disease 136 37
Hematopoietic system disease 23 48
Immune system disease 80 29
Integumentary system disease 78 44
Nervous system disease 195 468
Reproductive system disease 51 0
Respiratory system disease 62 0
Thoracic disease 9 0
Urinary system disease 56 9
Disease of cellular proliferation 811 4
Cancer 659 2
Benign neoplasm 157 2
Pre-malignant neoplasm 22 0
Disease of mental health 2 41
Genetic disease 3 176
Physical disorder 0 12
Syndrome 11 27
1Data was extracted from the November 2017 release of DO.
Table 5. Resources used in disease term review and addition
Resource URL
Online Mendelian Inheritance
in Man (OMIM)
omim.org
Orphanet www.orpha.net
Genetics Home Reference ghr.nlm.nih.gov
GeneReviews www.ncbi.nlm.nih.gov/books/NBK1116
Medical Subject Headings (MeSH) meshb.nlm.nih.gov/search
8
RESOURCE ARTICLE Disease Models & Mechanisms (2018) 11, dmm032839. doi:10.1242/dmm.032839
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Acknowledgements
The Disease Ontology project would like to acknowledge the efforts of DO’s
engineering team members, Michael Schor and Victor Felix. We would like to thank
the RGD and MGD curation and software staff who contribute to the success of
these resources.
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: M.S., C.L.S., J.T.E., L.M.S.; Methodology: S.M.B., E.M., S.J.F.L.,
L.M.S.; Validation: E.M., L.M.S.; Investigation: S.M.B., E.M., S.J.F.L.; Writing -
original draft: S.M.B.; Writing - review & editing: S.M.B., M.S., E.M., S.J.F.L., C.L.S.,
L.M.S.; Supervision: M.S., C.L.S., J.T.E., L.M.S.; Funding acquisition: M.S.,
J.T.E., L.M.S.
Funding
The Mouse Genome Database (MGD), Rat Genome Database (RGD) and Disease
Ontology coordination activities described here were supported by the National
Institutes of Health – National Human Genome Research Institute [supplement to
grant number: 3U41HG000330-27S2]. RGD is funded by the National Institutes of
Health – National Heart, Lung, and Blood Institute [grant number: 3R01HLB64541]
and MGD is funded by the National Institutes of Health – National Human Genome
Research Institute [grant number: 5U41HG000330].
References
Amberger, J. S. and Hamosh, A. (2017). Searching online mendelian inheritance
in man (OMIM): A knowledgebase of human genes and genetic phenotypes.Curr.
Protoc. Bioinformatics. 58, 1.2.1-1.2.12.
Bello, S. M., Richardson, J. E., Davis, A. P., Wiegers, T. C., Mattingly, C. J.,
Dolan, M. E., Smith, C. L., Blake, J. A. and Eppig, J. T. (2012). Disease model
curation improvements at Mouse Genome Informatics. Database 2012, bar063.
Bertoldi, L., Forcato, C., Vitulo, N., Birolo, G., De Pascale, F., Feltrin, E.,
Schiavon, R., Anglani, F., Negrisolo, S., Zanetti, A. et al. (2017). QueryOR: a
comprehensive web platform for genetic variant analysis and prioritization. BMC
Bioinformatics 18, 225.
Blake, J. A., Eppig, J. T., Kadin, J. A., Richardson, J. E., Smith, C. L., Bult, C. J.
and the Mouse Genome Database Group (2017). Mouse Genome Database
(MGD)-2017: community knowledge resource for the laboratory mouse. Nucleic
Acids Res. 45, D723-D729.
Campbell, M. P. and Packer, N. H. (2016). UniCarbKB: new database features for
integrating glycan structure abundance, compositional glycoproteomics data, and
disease associations. Biochim. Biophys. Acta Gen. Subj. 1860, 1669-1675.
Cheng, L., Jiang, Y., Wang, Z., Shi, H., Sun, J., Yang, H., Zhang, S., Hu, Y. and
Zhou, M. (2016). DisSim: an online system for exploring significant similar
diseases and exhibiting potential therapeutic drugs. Sci. Rep. 6, e99415.
Davis, A. P., Wiegers, T. C., Rosenstein, M. C. and Mattingly, C. J. (2012).
MEDIC: a practical disease vocabulary used at the Comparative Toxicogenomics
Database. Database 2012, bar065.
Eppig, J. T., Smith, C. L., Blake, J. A., Ringwald, M., Kadin, J. A., Richardson,
J. E. and Bult, C. J. (2017). Mouse Genome Informatics (MGI): resources for
mining mouse genetic, genomic, and biological data in support of primary and
translational research. Methods Mol. Biol. 1488, 47-73.
Farlow, J., Pankratz, N. D., Wojcieszek, J. and Foroud, T. (2004). Parkinson
Disease Overview. In GeneReviews® (ed. M. P. Adam, H. H. Ardinger, R. A.
Pagon, S. E. Wallace, L. J. H. Bean, K. A. A. Stephens). Seattle: University of
Washington.
Fernandez-Llimos, F., Minguet, F. and Salgado, T. M. (2017). New pharmacy-
specific Medical Subject Headings included in the 2017 database. Am. J. Heal.
Pharm. 74, 1128-1129.
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos,
A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L. et al. (2017).
CIViC is a community knowledgebase for expert crowdsourcing the clinical
interpretation of variants in cancer. Nat. Genet. 49, 170-174.
Hayman, G. T., Laulederkind, S. J. F., Smith, J. R., Wang, S.-J., Petri, V., Nigam,
R., Tutaj, M., De Pons, J., Dwinell, M. R. and Shimoyama, M. (2016). The
Disease Portals, disease–gene annotation and the RGD disease ontology at the
Rat Genome Database. Database 2016, baw034.
Hoehndorf, R., Gruenberger, M., Gkoutos, G. V. and Schofield, P. N. (2015).
Similarity-based search of model organism, disease and drug effect phenotypes.
J. Biomed. Semantics 6, 6.
Kibbe, W. A., Arze, C., Felix, V., Mitraka, E., Bolton, E., Fu, G., Mungall, C. J.,
Binder, J. X., Malone, J., Vasant, D. et al. (2015). Disease Ontology 2015
update: an expanded and updated database of human diseases for linking
biomedical knowledge through disease data. Nucleic Acids Res. 43,
D1071-D1078.
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